Look­ing for 'ex­ter­nal in­no­va­tion,' Boehringer In­gel­heim re­serves $500M+ for new Shang­hai hub

Now that Boehringer In­gel­heim’s bet on con­tract man­u­fac­tur­ing in Chi­na has paid off, the Ger­man drug­mak­er is an­te­ing up more to get in­to the re­search game.

Boehringer has set aside $507.9 mil­lion (€451 mil­lion) for a new Ex­ter­nal In­no­va­tion Hub to be built in Shang­hai over five years. The site will be­come one of its “strate­gic pil­lars” as the team strives to get 71 ap­provals — ei­ther for new prod­ucts or in­di­ca­tions — by 2030, said Fe­lix Gutsche, pres­i­dent and CEO of Boehringer In­gel­heim Chi­na.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA